Molex company Phillips Medisize has introduced TheraVolt Medical Connectors to enhance integration, performance and functionality of the devices, addressing the needs of medical device engineers.
The launch marks the company’s entry into the medical connector market under its own brand.
Go deeper with GlobalData
These connectors aim to meet the increasing demand, spurred by the quick adoption of pulsed field ablation (PFA) technology.
They are said to offer improved functionality, handling both signals and high-voltage lines.
TheraVolt Medical Connectors claim to have cross-platform compatibility, which simplifies device integration, extends the life of capital equipment, and minimises both customisation development time and expenses.
This is particularly beneficial for the companies that develop PFA treatments for individuals with atrial fibrillation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe connectors offer several key features, including high pin count and voltage clearance, which facilitate the integration of additional functionalities into multi-therapy medical devices.
They also provide flexibility of the design and customisation, with off-the-shelf availability and options for tailoring to specific application demands.
Sterilisation compatibility is another key feature, as TheraVolt Medical Connectors are designed to withstand several autoclave cycles without compromising integrity and performance.
Additionally, they are designed for safety and reliability, supporting compliance with IEC and IPC needs for dependable operation in medical applications.
Phillips Medisize has announced that further medical connectors are currently being developed and are expected to be released in the next 18 to 24 months.
Phillips Medisize medtech segment vice-president Pete Soupir said: “With the launch of TheraVolt, the first of several Phillips Medisize–branded connectors, we are excited to bring deeper collaboration and innovation to complement our exceptional contract design and manufacturing services and proven Molex connectivity solutions to our medtech customers.”
In 2023, Phillips Medisize partnered with GlucoModicum, a Finland-based medtech company, to work on a non-invasive, needle-free continuous glucose monitor.
